RussianPatents.com

Crystalline beta-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2h-1,4-benzodiazepin-2-one and synthesis method thereof. RU patent 2430094.

FIELD: chemistry.

SUBSTANCE: described is a novel crystalline β-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one (phenazepam) and synthesis method thereof, which can be used in pharmaceutical industry and medicine as a tranquilliser. Said novel crystalline β-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one is characterised by certain interplanar spacing (A⁰) and corresponding intensity and parameters of the crystal lattice, given in the claims.

EFFECT: marked muscle relaxant, soporific, anticonvulsant and anxiolytic action.

2 cl, 7 ex, 2 tbl, 9 dwg

IPC classes for russian patent Crystalline beta-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2h-1,4-benzodiazepin-2-one and synthesis method thereof. RU patent 2430094. (RU 2430094):

C07D243/26 - Preparation from compounds already containing the benzodiazepine skeleton

C07D243/24 - Oxygen atoms

A61P25/22 - Anxiolytics

A61K31/5513 -

Another patents in same IPC classes:

[<sup>3</sup>h]-7-chloro-1,3-dihydro-1-methyl-5-phenyl-2h-1,4- benzdiazepine-2-one high-labeled with tritium and method for its preparing

[³h]-7-chloro-1,3-dihydro-1-methyl-5-phenyl-2h-1,4- benzdiazepine-2-one high-labeled with tritium and method for its preparing / 2247116
Invention describes [3H]-7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzdiazepine-2-one high-labeled with tritium of the formula (I): . Also, invention describes methods for preparing [3H]-7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzdiazepine-2-one high-labeled with tritium. Invention provides preparing diazepam analog high-labeled with tritium that can be used in carrying out medical-biological investigations and can be used in biology and medicine.

S-adenosylmethionine compositions for peroral application / 2427376
Claimed are dietary and/or nutriceutic pharmaceutical composition for peroral application which contains S-adenosylmethi-onine-para-toluolsulfonate (SAMe) in combination with inositol and/or ino-sitol-1-phosphate and pharmaceutically acceptable excipients, in which at least one of and pharmaceutically acceptable excipients represents magnesium oxide in concentration from approximately 1.0 to approximately 10.0% of composition weight (versions), method of its obtaining, method of stabilisation of hard food and/or nutriceutic pharmaceutical composition based on SAMe-para-toluolsulfonate by application of inositol and/or inositol-1-phosphate, application of SAMe-para-toluolsulfonate in combination with inositol and/or inositol-1-phosphate for obtaining composition for treatment of depressive states and panic syndromes.

Alkyl sulphonamide quinolines with affinity to nk-3 receptors / 2421447
Compound is ((S)-1-phenyl-propyl)-amide 3-(methane sulphonyl amino)-2-phenyl- quinoline-4-carboxylic acid, stereoisomer, enantiomer or pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on the disclosed compound.

Polymorphic modification in n-{5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-2-fluoro-phenyl}-n-methyl-acetamide (versions), containing it pharmaceutical composition (versions), medication, method of obtaining said polymorphic modification (versions) and method of treatment and/or prevention of nervous disorders / 2413729
Claimed invention describes novel polymorphic modification N-{5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-2-fluoro-phenyl}-N-methyl-acetamide, methods of its obtaining, its application as medication, its application for preparation of medication and pharmaceutical compositions, including novel polymorphic modification.

Anti-vomit nk-1 antagonist metabolites / 2404969
Invention relates to compounds of general formula (I) , where R is methyl and R1 is 4-methyl-oxy-piperazin-1-yl; or R is CH2OH and R1 is 4-methyl-piperzin-1-yl or 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof, as well as to a medicinal agent based on said compounds, having NK-1 receptor antagonist activity and to use of said compounds in treating NK-1 receptor associated diseases.

Substituted 8-sulphonyl-2,3,4,5-tetrahydro-1h-gamma-carbolines, ligands, pharmaceutical composition, synthesis method and use thereof / 2404180
Invention relates to novel substituted 8-sulphonyl-2,3,4,5-tetrahydro-1H-γ-carbolines of general formula 1 or pharmaceutically acceptable salts thereof, which are ligands with a wider range of simultaneous activity towards alpha adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors, sigma receptors, norepiniphrine receptors and serotonin receptors. In compounds of general formula 1 R1 is an amino group substitute selected from hydrogen; C1-C3alkyl optionally substituted with phenyl; C1-C4alkyloxycarbonyl; R2 is a cyclic system substitute selected from hydrogen, C1-C3alkyl optionally substituted with phenyl, pyridin-(3- or 4-yl), (6-methylpyridin-3-yl); C1-C3alkenyl substituted with phenyl; or optionally substituted phenylsulphonyl; R3 is an optionally halogen-substituted phenyl, six member aromatic azaheterocycle, mono- or di-C1-C3alkylamino group, phenylamino group which is optionally substituted with halogen atoms on the phenyl ring, or a substituted six member azaheterocycle containing an additional nitrogen atom, substituted with C1-C3alkyl.

Diarylmetyhylpyperazine derivatives, their obtaining and application / 2404172
There are described compound of formula, its pharmaceutically acceptable salt or their mixture, enentiomerically pure 4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)pyperazin-1-yl]-N,N-diethylbenzamide or its pharmaceutically acceptable salt. Also described are method of anxiety therapy, method of pain therapy and method of depression therapy in animal.

Substituted 4-phenyltetrahydroisoquinolines, preparation method, application as medicinal agents, and also medicinal agents containing them / 2398766
Invention refers to new compounds of formula I , where: R1, R2, R3 and R4 independently from each other mean hydrogen, F, CI, Br, I; R5 designates hydrogen, alkyl with 1, 2, 3, 4, 5 or 6 C atoms, or cycloalkyl with 3, 4, 5 or 6 C atoms; R6 designates hydrogen; R7 and R8 independently from each other mean hydrogen, W means CrH2r or CsH2S-2; and one or more CH2-groups in C2H2r and CsH2s-2 can be substituted with NR17, oxygen or S; R17 means hydrogen, alkyl with 1, 2, 3 or 4 C atoms; r means 1, 2, 3, 4, 5 or 6; s means 2, 3 or 4; X designates-with C(O)- or -S(O)2-; Z means -C(O)- or a bond; and also to their pharmaceutically acceptable salts and trifluoroacetates. The invention also concerns application of the compounds of formula I, and also to a pharmaceutical composition.

Anxiolytic and cerebroprotective agent reducing inclination to alcohol / 2393855
Invention refers to medicine, particularly to pharmacology and concerns application of derivatives of gamma-aminobutyric acid in the form of 4-amino-3-phenyl butane acid salts of general formula

Substituted 2-amino-3-sulfonyl-tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidines-antagonists of serotonin 5-ht<sub>6</sub> receptors, methods of producing and using said compounds

Substituted 2-amino-3-sulfonyl-tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidines-antagonists of serotonin 5-ht₆ receptors, methods of producing and using said compounds / 2384581
Invention relates to novel antagonists of serotonin 5-HT6 receptors - substituted 2-amino-3-sulfonyl-6,7,8,9-tetrahydro-pyrazolo[1,5-a]pyrido[3,4-e]pyrimidines of general formula 1 and substituted 2-amino-3-sulfonyl-5,6,7,8-tetrahydro-pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines of general formula 2 or their pharmaceutically acceptable salts and/or hydrates, method of producing said compounds and pharmaceutical compositions, medicinal agents and treatment method. In compounds of formula 1 and general formula 2 , Ar is phenyl which is possibly substituted with halogen atoms, or a 6-member nitrogen-containing heteroaryl; R1 is a hydrogen atom, C1-C3alkyl which is possibly substituted with phenyl, C1-C5alkoxycarbonyl; R2 is a hydrogen atom, halogen or C1-C3alkyl; R1 3 and R2 3 are optionally identical substitutes selected from a hydrogen atom, optionally substituted C1-C3alkyl or R1 3 and R2 3 together with the nitrogen atom with which they are bonded form a nitrogen-containing 6-member saturated heteroaryl optionally substituted with C1-C5alkoxycarbonyl, where the said heteroaryl has 1-2 heteroatoms selected from nitrogen.

4-(sulphanilpyrimidine-4-ylmethyl)morpholine derivatives as gaba-receptor ligands for treating anxiety, depression and epilepsy / 2382033
Invention refers to compound of formula I wherein X represents -S- or -NH-; R1 represents C1-12alkyl, C2-12alkenyl, phenyl C1-12alkel, phenyl C2-12alkenyl or phenyl-O-C1-12alkyl and wherein said phenyl groups are optionally substituted with one or two assistants chosen from the group consisting of lower C1-7alkyl, C C1-7alkoxy and halogen C1-7alkyl; R2 represents hydrogen, lower C1-7alkyl or C3-6cycloalkyl; R3/R4 together with N-atom whereto attached, form nonaromatic 5,6-members heterocyclic ring system which optionally contains in addition to N-atom one additional heteroatom chosen from the group, consisting of O or N and where the ring system is optionally substituted group lower C1-7alkyl, lower C1-7alkoxy, -NR2, -CONR2; or R3/R4 together with N-atom whereto attached, can form heterocyclic ring system which contains at least two rings and which optionally contains one or two additional heteroatoms chosen from group, consisting of N and O; R represents hydrogen or lower C1-7alkyl; R5 represents hydrogen or lower C1-7alkyl; or to pharmaceutically acceptable additive salts with acid of this compound. The invention also concerns a medical product.

2,4-di(aminophenyl)pyrimidines as plk-kinase inhibitors / 2404979
Invention refers to new compounds exhibiting antiproliferative activity of formula (1) where W means N or C-R2; X means -NH-; Y means CH; Z means halogen, -NO2, C2-C3alkynyl-, halogen-C1-C3alkyl- and -C(=O)-C1-C3alkyl, A means a group of formula (i), (ii) or (iii) Q1 means phenyl; B1, B2, B3 and B4 independently mean C-RgRh, N-Ri or O; R1 means hydrogen; R2 means a residue specified from the group including hydrogen, halogen and -OR4; Ra, Rb, Rc, Rd, Re and Rf independently mean hydrogen; Rg and Rh independently mean a residue specified from the group including hydrogen, =O, -OR4 and -NR4C(=O)R5; or mean optionally a residue monosubstituted or twice-substituted with equal or different substitutes and specified from the group including C1-C6alkyl and phenyl, the substitute/substitutes is/are specified from the group including R8/, -OR4, -C(=O)R4, -C(=O)OR4 and -C(=O)NR4R5 where R8/ and other values of radicals are specified in the patent claim, optionally in the form of their pharmacologically noncontaminating acid addition salts. The invention also concerns a pharmaceutical composition.

Method for treatment of drug-resistant epilepsy / 2404777
Invention relates to medicine, namely to dietology and neurology, and relates to treatment of drug-resistant epilepsy. For this purpose ketogenic dietary treatment is administered with monitoring of glucose level in blood and ketone bodies in urine. The first stage includes hungry phase with duration of not more than a day, which is interrupted as level of ketone bodies reaches 8-10 millimole/l or as glucose level in blood becomes lower than 3.5 millimole/l, independently on level of ketone bodies. At the second stage, high-fat cocktail is introduced during the day in three stages, having high ketogenic ratio of components. Then independently on level of ketone bodies, the third stage is started, including individual basis ketogenic food ration, at the same time, if therapeutic level of ketone bodies is not obtained at the first and second stages, at the third stage in daily ration 1-2 food intakes are substituted with high-fat cocktail, and in case ketonuria is not available in this case as well, basic food ration is recalculated with correction of its nutrition value.

Method of differential diagnostics of post-stroke affective disorders / 2391912
Invention relates to medicine, namely to nervous diseases. Strength of excitation processes and mobility of nervous processes are determined by J.Strelyau personality questionnaire. If strength of nervous processes in excitation is 42 points and higher, in nervous processes motility is 42 points and higher minimal day dose of antidepressants or psychotherapy is administered. If strength of nervous processes in excitation is lower than 42 points, motility of nervous processes lower than 42 points - maximal day dose of antidepressants in combination with psychotherapy is administered. If strength of nervous processes in excitation is lower than 42 points, motility of nervous processes is higher than 42 points maximal day dose of antidepressants in combination with psychotherapy is administered.

Pharmaceutical composition containing benzodiazepine derivatives and rsv fusion protein inhibitor / 2388476
Invention relates to pharmaceutics and concerns a pharmaceutical composition for treatment and prevention of respiratory syncytial virus (RSV) including the respiratory syncytial virus (RSV) fusion protein and a benzodiazepine derivative capable of inhibiting RSV replication.

Method for decrease in bone resorption / 2373939
Invention refers to medicine, namely to methods of osteogenesis regulation and stimulation, decrease in bone resorption. Tranquilisers are introduced in psychic tension to prevent intensification of bone resorption.

Therapy of inhibited paranoid preschizophrenia / 2364422
Invention refers to medicine, namely to psychiatry, and can be used for treatment of patients suffering from a first episode of schizophrenia. The therapy involves single session of plasmapheresis by discrete method on the first day. Starting from the second day within 40 days, diazepam 0.5% is injected intramuscularly in a dose 2-2.5 ml 3 times a day during 2 to 21 day and in the same dose twice a day in the following days, in combination with Mexidol in a daily dose 600-800 mg introduced intravenously drop-by-drop two-intake within 10-12 days, for the following 10 days intravenously drop-by-drop in a dose 300-400 mg two-intake and 250-375 mg orally tableted two-intake until termination of the therapy. Thymogen 0.01% is introduced in a dose 1-1.2 ml intramuscularly every second day, 15 injections totally. On the 30th day of treatment, single dose 35-40 mg of prolonged Fluanxol. Said pharmacotherapy is combined with hyperbaric oxygenation of excess pressure 0.8-1.0 atmosphere at compression and decompression rate 0.1 atmospheres per minute and isopression period 40 minutes twice a day within the first 20 days and once a day within the next 20 days.

Heterocyclic condensed compounds useful as antidiuretic agents / 2359969
Invention is related to the compound of general formula 1 or its tautomer or pharmaceutically acceptable salt, where W selected from N and CR4; X is selected from CH(R8), O, S, N(R8), C(=O), C(=O)O, C(=O)N(R8), OC(=O), N(R8)C(=O), C(R8)-CH and C(=R8); G1 - bicyclic or tricyclic condensed derivative of azepin, selected from general formulas 2-9 , or derivative of aniline of common formula 10 , where A1, A4, A7 and A10 are independently selected from CH2, C=O, O and NR10; A2, A3, A9, A11, A13, A14, A15, A19 and A20 are independently selected from CH and N; or A5 stands for covalent connection, and A6 represents S; or A5 stands for N=CH, and A6 represents covalent connection; A8 , A12 , A18 and A21 are independently selected from CH=CH, NH, NCH3 and S; A16 and A17 both represent CH2, or one from A16 and A17 represents CH2, and the one another is selected from C=O, CH(OH), CF2, O, SOc and NR10; Y is selected from CH=CH or S; R1 and R2 are independently selected from H, F, Cl, Br, alkyl, CF3 and group O-alkyl; R3 is selected from H and alkyl; R4-R7 are independently selected from H, F, Cl, Br, alkyl, CF3, OH and group O-alkyl; R8 is selected from H, (CH2)bR9 and (C=O)(CH2)bR9; R9 is selected from H, alkyl, possibly substituted aryl, possibly substituted heteroaryl, OH, groups O-alkyl, OC(=O)alkyl, NH2, NHalkyl, N(alkyl)2, CHO, CO2H, CO2alkyl, CONH2, CONHalkyl, CON(alkyl)2 and CN; R10 is selected from H, alkyl, group COalkyl and (CH2)dOH; R11 is selected from alkyl, (CH2)dAr, (CH2)dOH, (CH2)dNH2, group (CH2)aCOOalkyl, (CH2)dCOOH and (CH2)dOAr; R12 and R13 are independently selected from H, alkyl, F, CI, Br, CH(OCH3)2, CHF2, CF3, groups COOalkyl, CONHalkyl, (CH2)dNHCH2Ar, CON(alkyl)2, CHO, COOH, (CH2)dOH, (CH2)dNH2, N(alkyl)2, CONH(CH2)dAr and Ar; Ar is selected from possibly substituted heterocycles or possibly substituted phenyl; a is selected from 1, 2 and 3; b is selected from 1, 2, 3 and 4; c is selected from 0, 1 and 2; and d is selected from 0, 1, 2 and 3. Besides, the invention is related to pharmaceutical compound and to method for activation of vasopressin receptors of type 2.

Method of scleroplasty operation anesthesia for 9 to 14 years old children / 2357727
Invention concerns medicine, particularly surgical ophthalmology, and can be applied in anesthetic support of scleroplasty operation for 9 to 14 years old children. Method involves administration of local anesthetic immediately before operation by triple instilling of visityl and alcaine mix in 1:1 ratio over 5 minutes to the eye to be under surgery. Mix of 0.5% seduxen solution and fentanyl solution mix is injected intravenously during surgical intervention. Each drug in the mix is taken in half amount of calculated dosage corresponding to age and weight of patient.

Derivatives of substituted dibenzoazepine and benzodiazepine, useful as inhibitors of γ -secretase / 2356895
Present invention pertains to new compounds with general formula I, where R1 represents -(CHR')q-aryl or -(CHR')q-thiophen, which are unsubstituted or mono-, di- or tri-substituted with (inferior)alkyl, (inferior)alkoxy, CF3 or haloid, or represents (inferior)alkyl, (inferior)alkenyl, -(CH2)n-Si(CH3)3, -(CH2)n-O-(inferior)alkyl, -(CH2)n-S- (inferior)alkyl, -(CH2)q-cycloalkyl, -(CH2)n-[CH(OH)]m-(CF2)p-CHqF(3-q), or represents -(CH2)n-CR2-CF3, where two radicals R together with a carbon atom form a cycloalkyl ring; R' represents hydrogen or (inferior)alkyl; n is 1, 2 or 3; m is 0 or 1; p is 0, 1,2, 3, 4, 5 or 6; q is 0, 1, 2 or 3; R2 represents hydrogen or (inferior)alkyl; R3 represents hydrogen, (inferior)alkyl, CH2F, aryl, optionally mono-, di- or tri-substituted with a haloid, or represents -(CH2)nNR5R6, where R5 and R6 independently represent hydrogen or (inferior)alkyl; R4 represents one of the following groups a) or b), where R7 represents inferior)alkyl or -(CH2)ncycloalkyl; R8 and R9 independently represent hydrogen, (inferior)alkyl, -(CH2)n-cycloalkyl or -C(O)-phenyl. The invention also relates to pharmaceutically used acid addition salts of these compounds, optically pure enantiomers, racemates or diastereomeric mixtures, as well as compounds with general formula I-1, and medicinal agent.

Therapy of postcontusional damaged retina / 2356520
Invention refers to medicine, namely to ophthalmology, and covers therapy of postcontusional damaged retina associated with visual dysfunctions. The therapy includes vitamin B complex combined with instilled nonsteroid antiinflammatory eye drops 3-5 times a day in dosage 2 drops within 7-10 days from the first day and cornea regeneration stimulators dosed 2 drops 3-4 times a day within 3-5 days, and oral day tranquilizers dosed 5-10 mg 1-2 times a day within 7-10 days. Besides, haemostatic agents are injected intramuscularly in dosage 1 ml once a day within 3-5 days as combined with daily intravenous droplet introduction of a composition including Panangin solution 20.0 ml, 5% Glucose solution 200.0 ml and Insulin 4 UN once a day within 3-5 days.